AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Elongation factor 1-alpha 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P68104

UPID:

EF1A1_HUMAN

Alternative names:

Elongation factor Tu; Eukaryotic elongation factor 1 A-1; Leukocyte receptor cluster member 7

Alternative UPACC:

P68104; P04719; P04720; Q6IQ15

Background:

Elongation factor 1-alpha 1 (EF1A1), also known as Eukaryotic elongation factor 1 A-1, plays a crucial role in protein synthesis. It catalyzes the GTP-dependent binding of aminoacyl-tRNA to ribosomes, facilitating the elongation phase of protein synthesis. This process is vital for the accurate and efficient production of proteins within the cell. EF1A1 is also involved in the positive regulation of IFNG transcription in T-helper 1 cells, highlighting its multifunctional role in cellular processes.

Therapeutic significance:

Understanding the role of Elongation factor 1-alpha 1 could open doors to potential therapeutic strategies. Its involvement in the fundamental process of protein synthesis and immune response regulation presents a unique opportunity for the development of novel treatments targeting a range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.